Navigation Links
Experimental vaccine sets sights on lung cancer
Date:11/30/2010

NEW YORK (Nov. 30, 2010) -- An experimental immunotherapy may someday become the newest weapon against lung cancer. Physician-scientists from Weill Cornell Medical College and Columbia University Medical Center are enrolling patients with non-small cell lung cancer (NSCLC) at NewYork-Presbyterian Hospital as part of an ongoing Phase III trial.

The experimental immunotherapy is intended to prevent cancer recurrence in patients who have already undergone surgical removal of the tumor. The therapy works by exposing the body to a protein called melanoma-associated antigen-A3 (MAGE-A3), normally produced by lung cancer cells.

"By exposing the body to the antigen, the immune system is primed to attack the cancer," says Dr. Nasser Altorki, principal investigator for the study at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, where he is a thoracic surgeon. He is also director of the Division of Thoracic Surgery and professor of cardiothoracic surgery at Weill Cornell Medical College.

The MAGE-A3 protein is classified as an Antigen-Specific Cancer Immunotherapeutic (ASCI). ASCIs are meant to trigger a specific response, telling antibodies and T-cells of the immune system to recognize and attack the cancer cells in a highly specific manner.

"We are hopeful that if this investigational therapy continues to show encouraging results in clinical trials that it may become a new weapon against non-small cell lung cancer," explains Dr. Joshua R. Sonett, the study's principal investigator at NewYork-Presbyterian Hospital/Columbia University Medical Center, where he is also chief of thoracic surgery and surgical director of the lung transplant program. He is also professor of surgery at Columbia University College of Physicians and Surgeons. "Because the vaccine augments the patient's own immune system, it may be less toxic to normal cells and can be used even when standard chemotherapy is needed. It is a win-win situation."


'/>"/>
Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... Calling all runners, walkers and everyone who wants to join ... annual “Lyme Walk & Run” will be held Sunday, April ... hosted by Lyme Research Alliance (LRA) & Tick-Borne ... and education about Lyme and other tick-borne diseases. , ... feature 5K and 10K runs and one-mile and three-mile Walks ...
(Date:3/31/2015)... Many people, including the ones with physical ... cycling are only for able-bodied participants. , A ... aims to change that thinking. , The program, ... Adaptive Sports Expo on Saturday, April 11 (10 a.m. ... Hollywood. , The event will showcase a wide ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Indosoft, developer of ... Asterisk 1.4 support in development of their 5.x line. The ... Asterisk has been deployed around the world for more than ... 1.4 as a telephony platform, Q-Suite can fully embrace newer ... quality call center software on Asterisk for more than a ...
(Date:3/31/2015)... KL Malaysia (PRWEB) March 31, 2015 ... need and requirement for education in a drastically different ... way in which learning and training content is being ... is being impacted by technology in an unprecedented way ... everyone, said Wemel Cumavoo, co-founder and CEO, My Mobile ...
(Date:3/31/2015)... March 31, 2015 The Walk a Mile ... GMO controversy , just kicked off their 3rd research sequence. ... equivalence.” , “ Substantial Equivalence was and is a ... Eric Battersby, Director at Change The World Films. “We ... well before GMOs even entered our food supply, just to ...
Breaking Medicine News(10 mins):Health News:Lyme Research Alliance & Tick-Borne Disease Alliance to Kick-Off 1st “Lyme Walk & Run” Event, April 26 2Health News:Memorial Healthcare System's Adaptive Sports Expo Encourages Physically Challenged To Go Beyond Perceived Limitations 2Health News:Indosoft Announces End of Life for Asterisk 1.4 Support in Q-Suite 5 Call Center Software 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 3Health News:The Walk a Mile Project Launches New Research Sequence on Substantial Equivalence of GMOs 2
... researchers led by scientists at Scripps Institution of Oceanography ... a tropical marine organism known to produce substances potentially ... cyanobacteria are some of the oldest forms of life ... blooms causes a threat to humans and animals. But ...
... 9 (HealthDay News) -- Could gastric bypass weight-loss surgery raise ... finding from a group of Swedish researchers who were slated ... Disease Week conference in Chicago. A team from the ... underwent primary bariatric surgery between 1980 and 2006. The patients ...
... Overdiagnosis and overtreatment of pulmonary embolism is a problem in ... use of computed tomography pulmonary angiography (CTPA), a new study ... blood clot in the lungs. CTPA was introduced in 1998 ... rapidly, according to background information in the study by Boston ...
... with torture is prohibited by international law and professional ... for doctors to do, argue two bioethicists. Their timely ... as news of the trail leading to the death ... Bay who were subject to "enhanced interrogation techniques," which ...
... Digestive Disease Week (DDW) is the largest international ... fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. ... Study of Liver Diseases, the American Gastroenterological Association ... and the Society for Surgery of the Alimentary ...
... MONDAY, May 9 (HealthDay News) -- An estimated one in ... an autism spectrum disorder, a new study says -- figures ... Estimates of autism prevalence in the United States generally ... or less than 1 percent. But those numbers may ...
Cached Medicine News:Health News:Genome of marine organism reveals hidden secrets 2Health News:Genome of marine organism reveals hidden secrets 3Health News:Risk for Problem Drinking May Rise After Gastric Bypass 2Health News:Scan Technology Tied to Overtreatment of Clots in Lungs 2Health News:A grim dilemma: Treating the tortured prisoner 2Health News:A grim dilemma: Treating the tortured prisoner 3Health News:UNC research highlights at 2011 Digestive Disease Week 2Health News:S. Korean Study Suggests Autism Rate May Be Much Higher 2Health News:S. Korean Study Suggests Autism Rate May Be Much Higher 3
(Date:3/31/2015)... -- Accelerated orthodontic treatment will be a featured ... Annual Session, May 15-19, as seven of the ... ® . Manufactured by OrthoAccel ® Technologies, ... a FDA-cleared, Class II medical device that speeds ... percent with just 20 minutes of daily use. ...
(Date:3/31/2015)... -- SCILEX Pharmaceuticals, Inc., a company engaged in the development ... pain, today announced that ITOCHU CHEMICAL FRONTIER Corporation (ICF, ... ITOCHU Corporation ( Tokyo : 8001; OTC-PINK: ... trading companies) in Japan , has ... closely with SCILEX as an advisor and development partner ...
(Date:3/31/2015)... , March 31, 2015  SynCardia Systems, Inc. has ... (IDE) clinical study on the effective use of its ... The FDA approval will ... as 30 heart failure patients. Patients enrolled in this ... as a bridge to a donor heart transplant. ...
Breaking Medicine Technology:Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3SCILEX Pharmaceuticals Announces Strategic Investment By ITOCHU CHEMICAL FRONTIER Corporation 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4
... patients will be tested,to determine the prevalence of ... major cooperative effort between the Alpha-1 Foundation,and the ... principal investigator is Robert A. Sandhaus, MD, PhD, ... and Research Center,in Denver. Sandhaus is also the ...
... Dec. 6 DURECT Corporation,(Nasdaq: DRRX ... III trial for Remoxy,had successfully met its ... the U.S. Food and Drug Administration (FDA) ... investigational drug based on,DURECT,s patented ORADUR(TM) technology, ...
Cached Medicine Technology:Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 2Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 2Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 3Primary Endpoint of Pivotal Phase III Clinical Trial Achieved for Remoxy(TM) 4
Our smallest port is available with either a COOK Peel-Away or COOK Micropuncture Introducer Set....
Small size means convenient set up in any cath lab. ,System so versatile it can be mounted on I.V. pole or bedside, or bagged in sterile field....
... vascular access. Hollow stylet design ... puncture with two-part needle. Initial ... while maintaining thumb position on ... hub of the stylet. Supplied ...
Used for placement of .035 inch (0.89 mm) or .038 inch (0.97 mm) diameter wire guides into the vascular system when a small 21 gage needle stick is desired....
Medicine Products: